- Home
- EOSE vs ATXS Comparison
EOSE vs ATXS Comparison
Compare EOSE & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EOSE
- ATXS
- Stock Information
- Founded
- EOSE 2008
- ATXS 2008
- Country
- EOSE United States
- ATXS United States
- Employees
- EOSE N/A
- ATXS N/A
- Industry
- EOSE Industrial Machinery/Components
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- EOSE Miscellaneous
- ATXS Health Care
- Exchange
- EOSE Nasdaq
- ATXS Nasdaq
- Market Cap
- EOSE 542.2M
- ATXS 516.4M
- IPO Year
- EOSE N/A
- ATXS 2015
- Fundamental
- Price
- EOSE $6.00
- ATXS $7.50
- Analyst Decision
- EOSE Strong Buy
- ATXS Strong Buy
- Analyst Count
- EOSE 6
- ATXS 5
- Target Price
- EOSE $5.42
- ATXS $25.60
- AVG Volume (30 Days)
- EOSE 10.5M
- ATXS 368.6K
- Earning Date
- EOSE 03-03-2025
- ATXS 03-03-2025
- Dividend Yield
- EOSE N/A
- ATXS N/A
- EPS Growth
- EOSE N/A
- ATXS N/A
- EPS
- EOSE N/A
- ATXS N/A
- Revenue
- EOSE $14,963,000.00
- ATXS N/A
- Revenue This Year
- EOSE $38.19
- ATXS N/A
- Revenue Next Year
- EOSE $832.93
- ATXS N/A
- P/E Ratio
- EOSE N/A
- ATXS N/A
- Revenue Growth
- EOSE 20.34
- ATXS N/A
- 52 Week Low
- EOSE $0.61
- ATXS $6.96
- 52 Week High
- EOSE $6.47
- ATXS $16.90
- Technical
- Relative Strength Index (RSI)
- EOSE 68.25
- ATXS 29.58
- Support Level
- EOSE $4.46
- ATXS $7.29
- Resistance Level
- EOSE $6.01
- ATXS $7.95
- Average True Range (ATR)
- EOSE 0.53
- ATXS 0.42
- MACD
- EOSE 0.01
- ATXS -0.08
- Stochastic Oscillator
- EOSE 76.67
- ATXS 15.25
About EOSE Eos Energy Enterprises Inc.
Eos Energy Enterprises Inc designs develop, manufactures, and markets zinc-based energy storage solutions for utility-scale, microgrid, and commercial & industrial (C&I) applications. The solutions are used in the utility sector, the renewable energy sector, and the industrial sector. It's flagship product Eos Znyth is a stationary battery energy storage system.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.